Owkin

Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors

OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of EP2/EP4 and DP1, with a first-in-class profile targeting select solid tumors in patients with high unmet need >100,000 patients per year in the US, EU4...

Owkin announces partnership with AstraZeneca to develop an AI gBRCA pre-screen solution for breast cancer

2 October 2024 -- Paris, France -- Owkin, the first end-to-end AI-biotech that uses cutting-edge causal AI to unlock precision drug discovery, development and diagnostics, is pleased to announce a new partnership with AstraZeneca, a global biopharmaceutical company, to develop an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology...
14/16 Bd Poissonnière, 75009 Paris